by Sue Robbins | Nov 11, 2020 | Migraine
As coronavirus cases surge in the United States and elsewhere, with little relief in sight, the world got good news on Monday. Pfizer and its partner, the German company, BioNTech, announced preliminary results that suggested their vaccine was more than 90 percent...
by Sue Robbins | Nov 10, 2020 | Migraine
Many people who get migraines experience worsening symptoms during extreme weather changes, hot or humid summer weather, or changes in barometric pressure. Several studies attempting to find a scientific correlation between weather and migraines have yielded...
by Sue Robbins | Nov 3, 2020 | Migraine
“Can you draw me a picture of your headache?” may sound like an unusual question – but drawings of headache pain provide plastic surgeons with valuable information on which patients are more or less likely to benefit from surgery to alleviate migraine headaches....
by Sue Robbins | Nov 2, 2020 | Migraine
Treatment with fremanezumab, the fully humanized IgG2?a monoclonal antibody that selectively targets calcitonin gene-related peptide, significantly reduced the number of headache or migraine days experienced before therapy. These findings, from a pooled analysis of...
by Sue Robbins | Oct 28, 2020 | Migraine
Fewer than one in three people with migraine took guideline-recommended prescription medication, data presented at the American Headache Society (AHS) annual scientific meeting showed. About 28% of survey respondents with mild to severe migraine-related...
by Sue Robbins | Oct 26, 2020 | Migraine
The first dual-purpose, external trigeminal nerve stimulation device to treat and prevent acute migraine is now available over the counter to adults over age 18. The Food and Drug Administration has cleared Cefaly Dual (Cefaly Technology) which was...
